Show simple item record

dc.contributor.authorNdlovu, Z
dc.contributor.authorMassaquoi, L
dc.contributor.authorBangwen, NE
dc.contributor.authorBatumba, JN
dc.contributor.authorBora, RU
dc.contributor.authorMbuaya, J
dc.contributor.authorNzadi, R
dc.contributor.authorNtabugi, N
dc.contributor.authorKisaka, P
dc.contributor.authorManciya, G
dc.contributor.authorMoudashirou, R
dc.contributor.authorPangani, H
dc.contributor.authorMangochi, P
dc.contributor.authorMakoko, R
dc.contributor.authorVan Laeken, D
dc.contributor.authorKwitonda, C
dc.contributor.authorRonoh, Y
dc.contributor.authorKuwenyi, K
dc.contributor.authorOrtuno, R
dc.contributor.authorMangwanya, D
dc.contributor.authorZvidzai, E
dc.contributor.authorMupepe, T
dc.contributor.authorZinyowera, S
dc.contributor.authorFajardo, E
dc.contributor.authorEllman, T
dc.date.accessioned2020-04-17T13:11:03Z
dc.date.available2020-04-17T13:11:03Z
dc.date.issued2020-04-03
dc.date.submitted2020-04-16
dc.identifier.pmid32243435
dc.identifier.doi10.1371/journal.pone.0230453
dc.identifier.urihttp://hdl.handle.net/10144/619616
dc.description.abstractBACKGROUND: In sub-Saharan Africa, a third of people starting antiretroviral therapy and majority of patients returning to HIV-care after disengagement, present with advanced HIV disease (ADH), and are at high risk of mortality. Simplified and more affordable point-of-care (POC) diagnostics are required to increase access to prompt CD4 cell count screening for ambulatory and asymptomatic patients. The Visitect CD4 Lateral Flow Assay (LFA) is a disposable POC test, providing a visually interpreted result of above or below 200 CD4cells/mm3. This study evaluated the diagnostic performance of this index test. METHODS: Consenting patients above 18years of age and eligible for CD4 testing were enrolled in Nsanje district hospital (Malawi), Gutu mission hospital (Zimbabwe) and Centre hopitalier de Kabinda (DRC). A total of 708 venous blood samples were tested in the index test and in the BD FACSCount assay (reference test method) in the laboratories (Phase 1) to determine diagnostic accuracy. A total of 433 finger-prick (FP) samples were tested on the index test at POC by clinicians (Phase 2) and a self-completed questionnaire was administered to all testers to explore usability of the index test. RESULTS: Among 708 patients, 67.2% were female and median CD4 was 297cells/mm3. The sensitivity of the Visitect CD4 LFA using venous blood in the laboratory was 95.0% [95% CI: 91.3-97.5] and specificity was 81.9% [95% CI: 78.2-85.2%]. Using FP samples, the sensitivity of the Visitect CD4 LFA was 98.3% [95% CI: 95.0-99.6] and specificity was 77.2% [95% CI: 71.6-82.2%]. Usability of the Visitect CD4 LFA was high across the study sites with 97% successfully completed tests. Due to the required specific multiple incubation and procedural steps during the Visitect CD4 LFA testing, few health workers (7/26) were not confident to manage testing whilst multi-tasking in their clinical work. CONCLUSIONS: Visitect CD4 LFA is a promising test for decentralized CD4 screening in resource-limited settings, without access to CD4 testing and and it can trigger prompt management of patients with AHD. Lay health cadres should be considered to conduct Visitect CD4 LFA testing in PHCs as well as coordinating all other POC quality assurance.en_US
dc.language.isoenen_US
dc.publisherPublic Library of Scienceen_US
dc.rightsWith thanks to Public Library of Science.en_US
dc.titleDiagnostic performance and usability of the VISITECT CD4 semi-quantitative test for advanced HIV disease screeningen_US
dc.typeArticle
dc.identifier.eissn1932-6203
dc.identifier.journalPLoS Oneen_US
dc.source.journaltitlePloS one
dc.source.volume15
dc.source.issue4
dc.source.beginpagee0230453
dc.source.endpage
refterms.dateFOA2020-04-17T13:11:03Z
dc.source.countryUnited States


Files in this item

Thumbnail
Name:
Ndlovu et al 2020 Diagnostic ...
Size:
795.7Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record